Ivantis Gets $27M For Glaucoma Treatments

Ivantis, an Irvine-based developer of treatments for glaucoma, said today that it has raised $27.0M in a Series B funding round. According to Ivantis, the round was led by Ascension Health Ventures, and also included prior investors New Enterprise Associates, Delphi Ventures, and new investors, including MemorialCare Innovation Fund. Ivantis said the new funding round will go towards four randomized trials it is running across the world. Ivantis develops a minimally invasive, medical device used for glaucoma surgery, which helps to reduce eye pressure in glaucoma patients. The firm said its trail in the U.S. is evaluating its product in glaucoma patients who are undergoing cataract surgery, and the device is being used both in cataract surgery and in standalone glaucoma surgery internationally. Ivantis is led by Dave Van Meter. More information »